Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic discovery on nature of rheumatoid arthritis lung disease may offer patients therapy

10.01.2005


A discovery by a Mayo Clinic research team may pave the way for the creation of new drugs to treat rheumatoid arthritis (RA) lung disease, which affects an estimated 500,000 patients in the United States. Currently, there are no effective treatments for RA lung disease.

In a paper that appears in today’s online version of the Jan. 13 edition of Arthritis & Rheumatism, the researchers report that RA lung disease may operate much differently from other forms of lung disease. If further studies support this finding, it could change the way RA lung disease is treated as well as the design focus of drugs developed to treat it.

The Mayo Clinic research paper describes a staining method the team refined for identifying markers in RA patients’ lung tissues. The results establish two key points never before fully documented in the laboratory:

  • Certain specific T cells of the immune system, whose normal job in healthy people is to attack disease organisms that invade the body, are more abundant in tissue samples from patients with RA lung disease than in tissue samples from patients who have other forms of lung disease. This finding supports the concept that RA lung disease may be fundamentally different from other forms of lung disease -- and should be treated differently.


  • RA lung disease detection can be improved through the technological advance of computer-assisted image analysis. This improvement allows the disease to be diagnosed early and treated aggressively as a disease of the immune system.

Many doctors who have seen our results say, ’This is what I’ve always believed.’ But no one had proved it to them," says Carl Turesson, M.D., Ph.D., former Mayo Clinic research fellow now working at Malmo University Hospital in Sweden. Says Dr. Turesson, "Our work provides the evidence that was lacking, so from that standpoint, it is a very helpful demonstration that hopefully will lead to the development of new treatment strategies for RA lung disease."

The Investigation

In the Mayo Clinic laboratories, Dr.Turesson and colleagues examined 31 lung tissue biopsy specimens. Of those, 15 were from patients previously diagnosed with RA lung disease, and 16 were from patients who, although not suffering from RA lung disease, also had a disease affecting the lung tissue, interstitial lung disease. No one on the research team knew the diagnosis of a given specimen. All specimens were stained to enhance certain T cell subtypes and then examined by digital images magnified 100 times. The staining patterns were quantified using computer-assisted image analysis. Results from the 11,412 images analyzed indicated that tissue samples from RA lung disease patients consistently showed elevated numbers of a subset of T cells known as CD4 and CD3 cells.

Practical Implications of the Research

At least two immediate implications of this research could change the way researchers are attempting to design RA lung disease drugs and how aggressively RA lung disease patients are treated. First, the abundance of CD4 and CD3 cells in RA lung disease tissue suggests therapies specifically directed against T cells and T cell function may succeed where earlier therapeutic approaches did not. Explains Dr. Turesson: "This is a rationale for trying newer approaches to treating RA lung disease that involve drugs that block T cell action. That might help us make progress against this disease." Studies are ongoing to examine other important subtypes of cells involved in RA lung disease and to discover how these are related to its cause and the damage to the joints, lungs and other tissues of the body which result.

Second, data from the researchers shows that the form of RA disease that spreads beyond joints to involve the lungs is more likely to be fatal. However, if physicians can use the Mayo Clinic method for detecting early telltale signs of RA lung disease, they can decide to treat the disease aggressively in its early stages and thus potentially prolong lives, according to Dr. Turesson.

About Rheumatoid Arthritis

Rheumatoid arthritis belongs to a class of diseases in which the immune system erroneously attacks the body. These are called "autoimmune" diseases. Because it is a systemwide disorder that can affect different parts of the body, RA can cause a variety of symptoms. It can work silently for years without symptoms, as in the early stages of both joint damage and RA lung disease. Symptoms can include joint pain, stiffness, inflammation, persistent cough, shortness of breath and fever. RA affects an estimated 1 percent of the U.S. population, about 2.1 million Americans, according to the Arthritis Foundation, http://www.arthritis.org. Of these, nearly one-half may have some abnormal lung function. Up to one-fourth -- about 500,000 Americans -- develop RA lung disease. In RA lung disease, the air sacs of the lung (alveoli) and the structures that support them become so damaged by inflammation that they become scarred, impairing effective lung functioning.

Collaboration and Support

In addition to Dr. Turesson, other Mayo Clinic investigators included: Eric Matteson, M.D.; Thomas Colby, M.D.; Zvezdana Vuk-Pavlovic, Ph.D.; Robert Vassallo, M.D.; Henry Tazelaar, M.D.; and Andrew Limper, M.D. Cornelia Weyand, M.D., Ph.D., former Mayo Clinic rheumatologists, now working at Emory University in Atlanta, also collaborated.

Lisa Lucier | EurekAlert!
Further information:
http://www3.interscience.wiley.com/cgi-bin/jtoc/76509746/

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

17.10.2017 | Life Sciences

NASA finds newly formed tropical storm lan over open waters

17.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>